三顺SANSHUN品牌怎么样 申请店铺

我要投票 三顺SANSHUN在滴眼液行业中的票数:478 更新时间:2025-06-19
三顺SANSHUN是哪个国家的品牌?「三顺SANSHUN」是 长春普华制药股份有限公司 旗下著名品牌。该品牌发源于吉林省长春市,在1997年期间创立,经过多年的不懈努力和高速发展,现已成为行业的标杆品牌。

外推网助力三顺SANSHUN品牌出海!将品牌入驻外推网,定制三顺SANSHUN品牌推广信息,可以显著提高三顺SANSHUN产品曝光,简直是跨境电商爆单神器!目前仅需1000元/年哦~

三顺SANSHUN怎么样

始建于1997年,以生产中成药、生化学药品为主的综合性企业,其复方熊胆滴眼液对于治疗细菌性眼结膜炎、流行性角结膜炎有显著功效


长春普华制药股份有限公司始建于1997年11月,主要从事中成药、化学药品的研发、生产和销售,是吉林省高新技术企业、GMP认证企业。公司坐落于美丽的北方春城长春市,位于高新产业技术开发区火炬路1105号,占地面积27000平方米,GMP车间及建筑面积约12000平方米。

长春普华制药股份有限公司是融研发、生产、销售于一体,以生产中成药、生化学药品为主的综合性制药企业。公司拥有生产设备,科学的管理体系,雄厚的研发力量,产品质量及精锐的销售队伍。公司产品涉及五官科、皮肤科、肌肉-骨骼系统疾病、心脑血管疾病、呼吸系统疾病等多个医疗领域,涵盖了滴眼剂、膏剂、小容量注射剂、滴丸剂、片剂、胶囊剂、颗粒剂、原料药等剂型。公司已形成“以中成药为特色,以眼科用药和皮肤科用药为主,肌肉骨骼系统及其他领域用药为辅”的产品格局,主要产品包括复方熊胆滴眼液、苄达赖氨酸滴眼液、近视乐眼药水、丹皮酚软膏、辣椒碱乳膏、益心酮滴丸等,产品特色鲜明,在特定治疗领域和细分市场具有独特的竞争优势。在产品储备方面,公司拥有多个具备产业化条件且市场潜力大的优质产品。

公司新药研发实力雄厚,拥有一支以研发人员为主的新药研发队伍。多年来在基因工程药物、现代中药等领域投入了大量研发资金,一批具有自主知识产权的高水平新药已经进入新药申报程序,为公司的发展奠定了坚定的基础。

公司以“服务社会、承担责任、关注员工、共同成长”为企业经营理念,以“责任、忠诚、执行、敬业、荣誉”为企业精神,经营水平不断提高,营销网络遍布全国各地,优质的产品受到患者的一致好评。


Founded in 1997, it is a comprehensive enterprise mainly engaged in the production of Chinese patent medicine and biochemical medicine. Its compound bear bile eye drops have significant effect on the treatment of bacterial conjunctivitis and epidemic keratoconjunctivitis. Changchun Puhua Pharmaceutical Co., Ltd. was founded in November 1997, mainly engaged in the research, development, production and sales of Chinese patent medicine and chemical medicine. It is a high-tech enterprise and GMP certified enterprise in Jilin Province Industry. The company is located in the beautiful North Spring City Changchun City, No. 1105, Torch Road, hi tech Development Zone, covering an area of 27000 square meters, GMP workshop and building area of about 12000 square meters. Changchun Puhua Pharmaceutical Co., Ltd. is a comprehensive pharmaceutical enterprise integrating R & D, production and sales, focusing on the production of proprietary Chinese medicine and biochemical drugs. The company has production equipment, scientific management system, strong R & D force, product quality and excellent sales team. Our products cover many medical fields, such as facial features, dermatology, musculoskeletal system diseases, cardiovascular and cerebrovascular diseases, respiratory system diseases, etc., including eye drops, poultices, small volume injections, pills, tablets, capsules, granules, APIs and other dosage forms. The company has formed a product pattern of "with Chinese patent medicine as the feature, ophthalmology and dermatology as the main drug, musculoskeletal system and other fields as the auxiliary drug". The main products include compound bear bile eye drops, benzyl lysine eye drops, myopic eye drops, paeonol ointment, capsaicin cream, yixinke pills and so on. The products have distinctive characteristics and are subdivided in specific treatment fields The market has a unique competitive advantage. In terms of product reserve, the company has a number of high-quality products with industrialization conditions and great market potential. The company has strong R & D strength of new drugs, with a new drug R & D team mainly composed of R & D personnel. Over the years, a large number of R & D funds have been invested in the fields of genetic engineering drugs, modern Chinese medicine and so on. A batch of high-level new drugs with independent intellectual property rights have entered the new drug application process, laying a solid foundation for the development of the company. The company takes "serving the society, taking responsibility, paying attention to employees and growing up together" as its business philosophy, and "responsibility, loyalty, implementation, dedication and honor" as its corporate spirit. Its business level is constantly improving. Its marketing network is spread all over the country, and its high-quality products are highly praised by patients.

本文链接: https://brand.waitui.com/056f4e0ca.html 联系电话:请联系客服添加 联系邮箱:请联系客服添加

外推网广告位招租,每天只要9块9

7×24h 快讯

MiniMax考虑赴港IPO?知情人士:属实,仍处于初步筹备阶段

AI独角兽稀宇科技(MiniMax)正考虑在香港进行首次公开募股(IPO)。6月18日,接近MiniMax的知情人士表示,MiniMax内部确实有类似想法,但目前仍处于初步筹备阶段。MiniMax成立于2021年,2024年3月,MiniMax获6亿美元A轮融资,投后估值25亿美元,由阿里巴巴领投,此前融资的投资方也包括腾讯等。据媒体报道称,MiniMax的实际估值目前已经超过2024年所报道过的“25亿美元”。(澎湃)

2小时前

美国上周首次申领失业救济人数24.5万

美国劳工部6月18日公布数据显示,美国上周首次申领失业救济人数24.5万。(界面)

2小时前

美股大型科技股盘前多数上涨,奈飞涨0.6%

36氪获悉,美股大型科技股盘前多数上涨,截至发稿,奈飞涨0.6%,特斯拉涨0.37%,英伟达涨0.29%,Meta涨0.26%,亚马逊涨0.25%,苹果涨0.21%,谷歌涨0.18%;微软跌0.12%。

2小时前

热门中概股美股盘前多数下跌,阿里巴巴跌超1%

36氪获悉,热门中概股美股盘前多数下跌,截至发稿,阿里巴巴、哔哩哔哩、理想汽车跌超1%,京东跌0.76%,拼多多跌0.66%,微博跌0.41%,网易跌0.31%;蔚来涨0.73%,小鹏汽车涨0.35%。

2小时前

*ST华微:拟筹划股权协议转让事宜,明起停牌

36氪获悉,*ST华微发布公告,公司6月18日收到控股股东上海鹏盛的通知,为推动化解公司面临的资金占用规范类退市风险,其正在依规筹划所持有的公司股份协议转让事宜,该事项后续可能导致公司控制权发生变更。经申请,公司股票将于6月19日(星期四)上午开市起停牌,预计停牌时间不超过2个交易日。

2小时前

本页详细列出关于三顺SANSHUN的品牌信息,含品牌所属公司介绍,三顺SANSHUN所处行业的品牌地位及优势。
咨询